Filing identity and reporting period
Important identity mismatch: The supplied filing is Jupiter Wellness, Inc.’s Form 10-Q for the quarter ended June 30, 2022 (ticker JUPW), not BONK, INC. or a filing identified as BONK. Verify the issuer and filing before relying on this summary.
Jupiter Wellness develops, licenses and sells wellness products focused on hair, skin and sexual health, and reports a second business segment through SRM Entertainment, which supplies merchandise to theme parks. The financial statements are unaudited and cover the three and six months ended June 30, 2022, with 2021 comparisons.
Financial results and liquidity
| Metric | Three months ended June 30, 2022 | Three months ended June 30, 2021 | Six months ended June 30, 2022 | Six months ended June 30, 2021 |
|---|---|---|---|---|
| Revenue | $3.001 million | $595,088 | $3.722 million | $643,934 |
| Gross profit | $505,243 | $181,175 | $622,454 | $206,569 |
| Gross margin | 16.8% | 30.4% | 16.7% | 32.1% |
| Net loss | $1.441 million | $4.151 million | $4.361 million | $6.347 million |
| Basic loss per share | $0.07 | $0.37 | $0.19 | $0.56 |
Revenue increased sharply year over year; management attributed the 2021 comparison to COVID-19-related demand weakness and described demand as higher in 2022. Growth was concentrated in SRM: first-half SRM revenue was $3.682 million, versus $39,950 for Jupiter Wellness’s segment. Despite higher gross profit, gross margin contracted materially. First-half operating expenses included a $1.0 million impairment charge on a third-party note; interest expense was $574,656, including $501,927 of debt-discount amortization.
At June 30, cash was $5.001 million, down from $11.755 million at year-end 2021. Current assets were $10.648 million and current liabilities $3.068 million, implying working capital of approximately $7.579 million. Total assets were $14.386 million, total liabilities $3.689 million, and shareholders’ equity $10.697 million. The balance sheet reported convertible notes, net of discounts, of $1.397 million; the notes’ stated principal was $2.0 million. It also reported a $47,981 SBA loan and lease liabilities.
For the first half, operating cash use was $3.710 million. Investing cash use was $2.274 million, including $1.3 million paid for a clinical research agreement and $1.0 million advanced under a third-party note. Financing cash use was $770,782, including $2.777 million spent repurchasing shares, partly offset by debt proceeds. Cash declined by $6.754 million during the period.
Material changes and notable items
- First-half revenue rose to $3.722 million from $643,934, while net loss narrowed to $4.361 million from $6.347 million. Lower stock-based compensation was a significant factor in the lower reported expenses compared with 2021.
- The company funded $1.0 million of an additional secured note to Next Frontier Pharmaceuticals (NFP); after NFP terminated the acquisition agreement and the company issued a notice of default, Jupiter recorded a $1.0 million impairment in 2022. The filing also states that a $10.0 million impairment of the earlier NFP note was charged to 2021 earnings.
- In April 2022, Jupiter issued $2.0 million principal of convertible notes, due October 20, 2022, bearing 8% interest and convertible at $2.79 per share, and issued 1.46 million warrants. The notes include a potential downward conversion-price adjustment upon default.
- The company repurchased 2,690,354 shares for approximately $2.777 million through June 30, 2022. It reported 21,705,647 common shares issued and outstanding at quarter-end, excluding the separately presented treasury shares.
- Jupiter paid $1.3 million under a clinical research agreement, against an approximate $3.0 million budget, for research including post-COVID-19 syndrome and respiratory and skin conditions.
- The filing describes a continuing lawsuit involving Koch parties, with an unjust-enrichment counterclaim remaining and a jury trial scheduled no earlier than November 14, 2022. Management stated it knew of no other pending or threatened litigation expected to materially affect financial position, results or liquidity.
Outlook, risks and controls
The filing gives product-development expectations, not quantified financial guidance. Management said Photocil was expected to launch in the fourth quarter of 2022; a minoxidil booster launch in Japan and a sexual-wellness product launch were planned for 2023. An OTC eczema product was also planned for 2023. The company described a Phase 3 JW-100 study as in progress and said further development and potential FDA approval remain relevant to its therapeutic-product plans. These are forward-looking expectations, not assurances of launch, approval or revenue.
Risks evident in the filing include ongoing operating cash burn, lower gross margins, near-term convertible-note maturity, collection/default risk on the NFP note, clinical and regulatory uncertainty, dependence on purchase orders rather than long-term SRM customer contracts, and litigation. Nasdaq had raised equity-compensation listing-rule concerns; the filing says corrective actions were taken in July 2022 and the company regained compliance. Management concluded disclosure controls were effective as of June 30, 2022 and described remediation of previously reported internal-control weaknesses.
Key facts investors should verify
- Confirm the issuer: the source document is for Jupiter Wellness, Inc. (JUPW), not BONK, INC.
- Review the convertible notes’ October 20, 2022 maturity, repayment or conversion status, and any default-related terms.
- Assess cash runway, cash collections and the recoverability of the NFP note; the filing reports no 2022 impairment allowance beyond the $1.0 million charge described.
- Check whether planned product launches and clinical milestones occurred, and whether required regulatory approvals were obtained.
- Reconcile inconsistencies in the supplied filing text: it gives conflicting statements about cash equivalents, differing current lease-liability figures, and cash-flow section labels that do not align clearly with the listed activities. The text does not provide a clear reconciliation.
- Evaluate the material decline in gross margin and the concentration of reported revenue in SRM theme-park merchandise.